Synaffix
3 known investors
Synaffix develops antibody-drug conjugate (ADC) technology, providing linker-payload platforms that attach small-molecule, peptide, and protein-based payloads to antibodies for use in targeted cancer therapies. The company has been integrated into Lonza's Advanced Synthesis business platform.
Investors · 3
In the news
Frequently asked questions
- What does Synaffix do?
- Synaffix develops antibody-drug conjugate (ADC) technology, providing linker-payload platforms that attach small-molecule, peptide, and protein-based payloads to antibodies for use in targeted cancer therapies. The company has been integrated into Lonza's Advanced Synthesis business platform.
- Who are Synaffix's investors?
- Synaffix's investors include BOM, M Ventures, BioGeneration Ventures.